Compare Incyte Corporation (INCY) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Annaly Capital Management, Inc. — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Annaly Capital Management, Inc. trades at $22.6 (market cap $16.63B). The key difference: Incyte Corporation is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NLY | |
|---|---|---|
Market Cap | $23.11B | $16.63B |
Sector | Health | Financials |
52-Week High | $118.52 | $24.40 |
52-Week Low | $67.38 | $19.96 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NLY trades at $22.73, down 1.22% today, with a bullish technical signal and strong earnings beat history. The stock shows a low P/E of 7.42 and a 13% dividend yield, supported by recent analyst upgrades. Revenue grew to $2.24B in 2025, with net income margin at 91.17%, though cash flow from operations declined to $693M. The consensus price target is $24.80, implying 9% upside.
Outlook remains positive given earnings momentum and high yield, but risks include interest rate sensitivity and elevated debt-to-asset ratio of 23.55. Institutional sentiment is bullish with 57% buy ratings, though macroeconomic shifts could pressure mortgage REIT performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
